Antibody–cytokine fusion (immunocytokine): an anti-CD38 IgG linked to attenuated IFN-alpha2b that binds CD38+ myeloma/immune cells and delivers IFN to activate IFNAR/type I interferon signaling, driving direct antitumor effects and immune activation.
Modakafusp alfa is an anti-CD38 IgG4–IFN-alpha2b immunocytokine that binds CD38+ myeloma and immune cells and locally delivers interferon. The IFN-alpha moiety engages IFNAR to activate type I interferon signaling, inducing antiproliferative/apoptotic programs in CD38+ tumor cells and stimulating innate/adaptive immune responses.
NO
INDIRECT
Modakafusp alfa is targeted to CD38, not IFNAR2. After binding CD38+ cells, its IFN-alpha moiety engages IFNAR1/IFNAR2 to trigger type I interferon signaling, inducing antiproliferative/apoptotic effects in those CD38-bound cells; IFNAR2 expression alone is not sufficient for targeted killing.
Anti-CD38 monoclonal antibody that mediates ADCC, CDC, and ADCP and depletes CD38+ immunosuppressive cells.
Human IgG1κ anti-CD38 monoclonal antibody that binds CD38 on malignant plasma cells and other CD38+ cells, inducing Fc-mediated antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP); also depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), contributing to antitumor immunity.
YES
DIRECT
Daratumumab binds CD38 on target cells and engages immune effectors via its Fc to mediate ADCC (NK cells), ADCP (macrophages), and CDC (complement), leading to lysis/phagocytic clearance of CD38+ cells.
CDH6-directed antibody–drug conjugate; a monoclonal antibody targeting Cadherin-6 that is internalized and releases a deruxtecan (DXd; exatecan-derivative) topoisomerase I inhibitor payload to cause DNA damage and apoptosis.
CDH6-targeted antibody–drug conjugate; the anti-CDH6 mAb binds Cadherin-6 on tumor cells, is internalized, and releases a deruxtecan (DXd; exatecan-derivative) topoisomerase I inhibitor payload that induces DNA damage (single-strand breaks), leading to cell cycle arrest and apoptosis, with potential bystander killing.
YES
DIRECT
Anti-CDH6 antibody–drug conjugate binds CDH6 on tumor cells, internalizes, and releases a DXd topoisomerase I inhibitor that induces DNA damage (single-strand breaks), causing cell-cycle arrest and apoptosis, with potential bystander killing.
An intraperitoneal recombinant human–mouse chimeric bispecific T‑cell–engaging antibody (anti‑EpCAM × anti‑CD3) that binds EpCAM on tumor cells and CD3 on T cells to activate TCR/CD3 signaling and redirect cytotoxic T‑cell killing of EpCAM‑positive tumor cells for control of peritoneal tumor burden and ascites.
Bispecific antibody that binds EpCAM on tumor cells and CD3 on T cells, bringing them into proximity to activate TCR/CD3 signaling and redirect cytotoxic T-cell killing (perforin/granzyme and cytokine release) of EpCAM-positive tumor cells.
NO
INDIRECT
M701 engages CD3 on T cells and EpCAM on tumor cells, activating TCR/CD3 signaling to redirect T-cell killing (perforin/granzyme and cytokine release) of EpCAM+ tumor cells; CD3+ T cells are not the killed target.
CDH6-directed antibody–drug conjugate; a monoclonal antibody targeting Cadherin-6 that is internalized and releases a deruxtecan (DXd; exatecan-derivative) topoisomerase I inhibitor payload to cause DNA damage and apoptosis.
CDH6-targeted antibody–drug conjugate; the anti-CDH6 mAb binds Cadherin-6 on tumor cells, is internalized, and releases a deruxtecan (DXd; exatecan-derivative) topoisomerase I inhibitor payload that induces DNA damage (single-strand breaks), leading to cell cycle arrest and apoptosis, with potential bystander killing.
NO
INDIRECT
The ADC targets CDH6 on cell surfaces, is internalized, and releases deruxtecan to inhibit TOP1, causing DNA damage and apoptosis; TOP1 expression alone does not determine killing.